Anti-TNF therapy for juvenile idiopathic arthritis-related uveitis

References

• Kump LI Cervantes-Castañeda RA Androudi SN Foster CS Analysis of pediatric uveitis cases at a tertiary referral center Ophthalmology 2005 112 7 1287 1292 15921752
   PubMed Web of Science ®Google Scholar
• Rabinovich CE Use of tumor necrosis factor inhibitors in uveitis Curr Opin Rheumatol 2007 19 482 486 17762615
   PubMed Web of Science ®Google Scholar
• Holland GN A reconsideration of anterior chamber flare and its clinical relevance for children with chronic anterior uveitis (an American Ophthalmological Society thesis) Trans Am Ophthalmol Soc 2007 105 344 364 18427621
   PubMedGoogle Scholar
• Ravelli A Felici E Magni-Manzoni S Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease Arthritis Rheum 2005 52 3 826 832 15751057
   PubMed Web of Science ®Google Scholar
• Marvillet I Terrada C Quartier P Quoc EB Bodaghi B Prieur AM Ocular threat in juvenile idiopathic arthritis Joint Bone Spine 2009 76 383 388 19524473
   PubMed Web of Science ®Google Scholar
• Keenan JD Tessler HH Goldstein DA Granulomatous inflammation in juvenile idiopathic arthritis-associated uveitis J AAPOS 2008 12 6 546 550 18707906
   PubMed Web of Science ®Google Scholar
• Arnason JA Bell CL Juvenile rheumatoid arthritis: current concepts and practice J Pediatr Ophthalmol Strabismus 1995 32 6 383 385 8587023
   PubMed Web of Science ®Google Scholar
• Southwood TR Ryder CA Ophthalmological screening in juvenile arthritis: should the frequency of screening be based on the risk of developing chronic iridocyclitis? Br J Rheumatol 1992 31 9 633 634 1525633
   PubMedGoogle Scholar
• Chen CS Roberton D Hammerton ME Juvenile arthritis-associated uveitis: visual outcomes and prognosis Can J Ophthalmol 2004 39 6 614 620 15559647
   PubMed Web of Science ®Google Scholar
• Heinz C Mingels A Goebel C Fuchsluger T Heiligenhaus A Chronic uveitis in children with and without juvenile idiopathic arthritis: differences in patient characteristics and clinical course J Rheumatol 2008 35 1403 1407 18484686
   PubMed Web of Science ®Google Scholar
• Perez C Albert I DeFay K Zachariades N Gooding L Kriegler M A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to cell contact Cell 1990 63 251 258 2208285
   PubMed Web of Science ®Google Scholar
• Kriegler M Perez C DeFay K Albert I Lu SD A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF Cell 1988 53 45 53 3349526
   PubMed Web of Science ®Google Scholar
• Moss ML Jin SL Milla ME Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha Nature 1997 385 733 736 9034191
   PubMed Web of Science ®Google Scholar
• Baud V Karin M Signal transduction by tumor necrosis factor and its relatives Trends Cell Biol 2001 11 9 372 377 11514191
   PubMed Web of Science ®Google Scholar
• Grell M Wajant H Zimmermann G Scheurich P The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor Proc Natl Acad Sci U S A 1998 95 570 575 9435233
   PubMed Web of Science ®Google Scholar
• Alexander-Miller MA Derby MA Sarin A Henkart PA Berzofsky JA Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1–2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes J Exp Med 1998 188 1391 1399 9782116
   PubMed Web of Science ®Google Scholar
• Zheng L Fisher G Miller RE Peschon J Lynch DH Lenardo MJ Induction of apoptosis in mature T cells by tumour necrosis factor Nature 1995 377 348 351 7566090
   PubMed Web of Science ®Google Scholar
• Murray J Barbara J Dunkley SA Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirements for TNFR55 and TNFR75 for induction of apoptosis in vitro Blood 1997 90 7 2772 2783 9326245
   PubMed Web of Science ®Google Scholar
• Tracey KJ Cerami A Metabolic responses to cachectin/TNF. A brief review Ann N Y Acad Sci 1990 587 325 331 2193578
   PubMed Web of Science ®Google Scholar
• Sijssens KM Rijkers GT Rothova A Stilma JS Schellekens PA de Boer JH Cytokines, chemokines and soluble adhesion molecules in aqueous humor of children with uveitis Exp Eye Res 2007 85 443 449 17662277
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M Marcos Martín C Gallardo Galera JM Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis Ophthalmic Res 2001 33 251 255 11586057
   PubMed Web of Science ®Google Scholar
• Dick AD Forrester JV Liversidge J Cope AP The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU) Prog Retin Eye Res 2004 23 617 637 15388077
   PubMed Web of Science ®Google Scholar
• Sfikakis PP The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions Curr Dir Autoimmun 2010 11 180 210 20173395
   PubMedGoogle Scholar
• Knight DM Trinh H Le J Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 1993 30 1443 1453 8232330
   PubMed Web of Science ®Google Scholar
• Scallon BJ Moore MA Trinh H Knight DM Ghrayeb J Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 1995 7 251 259 7640345
   PubMed Web of Science ®Google Scholar
• Tracey D Klareskog L Sasso EH Salfeld JG Tak PP Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 2008 117 2 244 279 18155297
   PubMed Web of Science ®Google Scholar
• Furst DE Keystone EC Fleischmann R Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 Ann Rheum Dis 2010 69 Suppl 1 i2 i29 19995740
   PubMed Web of Science ®Google Scholar
• Mangge H Heinzl B Grubbauer HM El-Shabrawi Y Schauenstein K Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis Rheumatol Int 2003 23 5 258 261 12687288
   PubMed Web of Science ®Google Scholar
• Richards JC Tay-Kearney ML Murray K Manners P Infliximab for juvenile idiopathic arthritis-associated uveitis Clin Experiment Ophthalmol 2005 33 5 461 468 16181269
   PubMed Web of Science ®Google Scholar
• Rajaraman RT Kimura Y Li S Haines K Chu DS Retrospective case review of pediatric patients with uveitis treated with infliximab Ophthalmology 2006 113 2 308 314 16406545
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I Ayranci O Kasapcopur O Kir N Retrospective analysis of children with uveitis treated with infliximab J AAPOS 2008 12 6 611 613 18930672
   PubMed Web of Science ®Google Scholar
• Sharma SM Ramanan AV Riley P Dick AD Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease Ann Rheum Dis 2007 66 840 841 17170050
   PubMed Web of Science ®Google Scholar
• Kahn P Weiss M Imundo LF Levy DM Favorable response to high-dose infliximab for refractory childhood uveitis Ophthalmology 2006 113 5 860 864.e2 16545455
   PubMed Web of Science ®Google Scholar
• Zannin ME Birolo C Gerloni VM Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry J Rheumatol 2013 40 1 74 79 23118110
   PubMed Web of Science ®Google Scholar
• Medication Guide: ENBREL® (en-brel) (Etanercept) Thousand Oaks, CA Immunex Corporation 2008 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf Accessed May 26, 2010
   Google Scholar
• Smith JA Thompson DJ Whitcup SM A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis Arthritis Rheum 2005 53 18 23 15696578
   PubMed Web of Science ®Google Scholar
• Smith JR Levinson RD Holland GN Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease Arthritis Rheum 2001 45 252 257 11409666
   PubMed Web of Science ®Google Scholar
• Schmeling H Horneff G Etanercept and uveitis in patients with juvenile idiopathic arthritis Rheumatology (Oxford) 2005 44 1008 1011 15855187
   PubMed Web of Science ®Google Scholar
• Reiff A Takei S Sadeghi S Etanercept therapy in children with treatment-resistant uveitis Arthritis Rheum 2001 44 1411 1415 11407702
   PubMed Web of Science ®Google Scholar
• Reiff A Long-term outcome of etanercept therapy in children with treatment refractory uveitis Arthritis Rheum 2003 48 2079 2080 12847709
   PubMed Web of Science ®Google Scholar
• Foster CS Tufail F Waheed NK Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate Arch Ophthalmol 2003 121 437 440 12695239
   PubMed Web of Science ®Google Scholar
• Jap A Chee SP Immunosuppressive therapy for ocular diseases Curr Opin Ophthalmol 2008 19 6 535 540 18854699
   PubMed Web of Science ®Google Scholar
• [Humira approval letter for juvenile idiopathic arthritis] 2008 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s114ltr.pdf Accessed May 26, 2010
   Google Scholar
• Biester S Deuter C Michels H Adalimumab in the therapy of uveitis in childhood Br J Ophthalmol 2007 91 319 324 17035274
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB Flynn T Lehman TJ Adalimumab therapy for childhood uveitis J Pediatr 2006 149 572 575 17011337
   PubMed Web of Science ®Google Scholar
• Tynjälä P Kotaniemi K Lindahl P Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis Rheumatology (Oxford) 2008 47 3 339 344 18238789
   PubMed Web of Science ®Google Scholar
• Trachana M Pratsidou-Gertsi P Pardalos G Kozeis N Badouraki M Kanakoudi-Tsakalidou F Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis Scand J Rheumatol 2011 40 2 101 107 21108543
   PubMed Web of Science ®Google Scholar
• Kotaniemi K Säilä H Kautiainen H Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis Clin Ophthalmol 2011 5 1425 1429 22034564
   PubMedGoogle Scholar
• Saurenmann RK Levin AV Rose JB Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis Rheumatology (Oxford) 2006 45 8 982 989 16461435
   PubMed Web of Science ®Google Scholar
• Tynjälä P Lindahl P Honkanen V Lahdenne P Kotaniemi K Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis Ann Rheum Dis 2007 66 4 548 550 17068061
   PubMed Web of Science ®Google Scholar
• Simonini G Taddio A Cattalini M Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab Arthritis Care Res (Hoboken) 2011 63 612 618 21452272
   PubMed Web of Science ®Google Scholar
• Kay J Matteson EL Dasgupta B Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study Arthritis Rheum 2008 58 964 975 18383539
   PubMed Web of Science ®Google Scholar
• Shealy D Cai A Staquet K Characterization of golimumab (CNTO 148), a novel fully human monoclonal antibody specific for TNF-alpha MAbs 2010 2 4 428 439
   PubMed Web of Science ®Google Scholar
• Janssen Research and Development LLC A study of the safety and efficacy of CNTO 148 (golimumab) in children with juvenile idiopathic arthritis (JIA) and multiple joint involvement who have poor response to methotrexate (GO KIDS) Available from: http://clinicaltrials.gov/ct2/show/NCT01230827. NLM identifier: NCT01230827 Accessed January 9, 2014
   Google Scholar
• Cordero-Coma M Salom D Díaz-Llopis M López-Prats MJ Calleja S Golimumab for uveitis Ophthalmology 2011 118 9 1892.e3 e4 21889663
   PubMed Web of Science ®Google Scholar
• William M Faez S Papaliodis GN Lobo AM Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis J Ophthalmic Inflamm Infect 2012 2 4 231 233 22581347
   PubMedGoogle Scholar
• Choy EH Hazleman B Smith M Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial Rheumatology (Oxford) 2002 41 10 1133 1137 12364632
   PubMed Web of Science ®Google Scholar
• Sandborn WJ Feagan BG Stoinov S PRECISE 1 Study Investigators Certolizumab pegol for the treatment of Crohn’s disease N Engl J Med 2007 357 3 228 238 17634458
   PubMed Web of Science ®Google Scholar
• ESBATech AG Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis Available from: http://clinicaltrials.gov/show/NCT00823173. NLM identifier: NCT00823173 Accessed January 9, 2014
   Google Scholar
• Heiligenhaus A Thurau S Hennig M Grajewski RS Wildner G Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease Graefes Arch Clin Exp Ophthalmol 2011 248 11 1531 1551 20737162
   PubMed Web of Science ®Google Scholar
• Kakkassery V Mergler S Pleyer U Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment Curr Eye Res 2010 35 751 756 20673052
   PubMed Web of Science ®Google Scholar
• Reddy AR Backhouse OC Does etanercept induce uveitis? Br J Ophthalmol 2003 87 7 925 12812909
   PubMed Web of Science ®Google Scholar
• Taban M Dupps WJ Mandell B Perez VL Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature Ocul Immunol Inflamm 2006 14 3 145 150 16766397
   PubMed Web of Science ®Google Scholar